ILB 3000
Alternative Names: ILB-3000Latest Information Update: 28 Feb 2025
At a glance
- Originator Innolake Biopharm
- Class Antifibrotics; Monoclonal antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Fibrosis; Immunological disorders
Most Recent Events
- 07 Jan 2025 Early research in Fibrosis in China (Parenteral) before January 2025 (Innolake Biopharm pipeline, January 2025)
- 07 Jan 2025 Early research in Immunological disorders in China (Parenteral) before January 2025 (Innolake Biopharm pipeline, January 2025)